Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
A systematic review analyzed data from 32 phase III clinical trials on hypofractionated radiotherapy for prostate cancer, highlighting the lack of significant toxicity compared to external beam radiotherapy. The findings suggest that while brachytherapy may not be suitable for all patients, it remains a valuable treatment option.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.